A recent BrandWeek headline, "Why Pharma Fears Social Networking," continued the myth that pharma companies can't participate in social media.
While it's true that pharma has proceeded cautiously because of regulatory hurdles, most know it's important to participate
in social media, and are establishing pilot programs, mapping regulatory processes, or launching initiatives. It's time to
debunk the myth that pharma cannot employ social media.
Without detailed FDA guidance for marketing online, pharma has struggled to comply with FDA guidelines issued before the Internet
existed. The primary challenge was ensuring that commentary complies with established regulatory requirements, including:
1) presenting fair balance of benefits and risks, 2) reporting known adverse events to the FDA, and 3) not endorsing usage
for a condition not on FDA-approved labeling.
Fortunately, there are several easy ways to comply with regulatory requirements and ensure prompt posting of approved submissions.
These include expedited regulatory review processes, external third party pre-screens to reduce internal review volume, and
asking very specific questions rather than inviting unrestricted commentary.
The Social Media Significance
Patients and physicians are both heavy users of social media, giving pharma the opportunity to build stronger consumer and
professional relationships. By better understanding experiences, successes, frustrations, and needs, industry can respond
with better education and enhanced solutions, increasing compliance and grassroots treatment advocacy.
The opportunity to engage physicians is enormous. Manhattan Research reported in 2009 that 60 percent of doctors use, or are
interested in, Web 2.0 social applications. The same study found that physicians who reported using social media prescribed
24 more medications each week compared to physicians not using it.
Pharma can also benefit from a deeper dialogue with patients, who increasingly use social media to manage their healthcare.
In 2008, the Pew Research Center reported that 80 percent of online consumers search for health-related information, encompassing
official and unofficial sources. Furthermore, an iCrossing 2008 report said that 34 percent of health searchers use social
media resources, and 75 percent seek other consumers to exchange information with.
Few Problem Postings
Available data indicates that problematic commentary on social media will be far less than feared. The vast majority of social
media behavior consists of observing rather than participating, so pharma's current monitoring and response resources should
be able to handle the volume.
Nielsen BuzzMetrics studied 500 messages across disease topics on Google and Yahoo's health sites, and found only one adverse
event reported—a caregiver whose mother asked the community whether fluid retention, not listed as a side effect, might mean
her chemotherapy medication was working. Similarly, J&J's
http://childrenwithdiabetes.com/, a community site for parents of kids with diabetes, allows people to post whatever they want, and J&J's site-monitoring
reported fewer adverse events than expected.
Web usability guru Jakob Nielsen and Hitwise's Bill Tancer separately analyzed top social sites, and identified extremely
low participation rates. Their 1-9-90 rule (see chart) indicates that only a fraction of Web 2.0 visitors contribute/comment,
meaning pharma will likely encounter few problem postings to which they must respond.
THE 1-9-90 RULE OF WEB 2.0 SITES